Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 9fludarabine 8Interleukin-2 8aldesleukin 7Sunitinib 6Everolimus 6Bevacizumab 6fludarabine phosphate 5Sorafenib 5Radiotherapy 4Nivolumab 4Gene Expression Profiling 4Filgrastim 4pembrolizumab 3peginterferon alfa-2b 3Stem Cell Transplantation 3Radiotherapy, Intensity-Modulated 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3cabozantinib 2atezolizumab 2Thiotepa 2Sodium Chloride 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Mycophenolic Acid 2Mesna 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Kidney Neoplasms × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡